A cross-sectional study to investigate the association between the Skin condition and Advanced Glycation Endproducts.
- Conditions
- Healthy adult
- Registration Number
- JPRN-UMIN000052271
- Lead Sponsor
- niversity of Miyazaki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 42
Not provided
1. Subjects who answered in the self-reported health questionnaire that they currently have a skin disease that requires treatment. 2. Subjects who answered in the self-reported health questionnaire that they have had or are currently suffering from respiratory, gastrointestinal,hepatic/gallbladder/pancreatic, hematologic, renal, endocrine, cardiovascular and/or mental disease that requires hospital treatment. 3. Subjects who had a serious injury or surgical history within 12 weeks prior to this study. 4. Heavy smokers (more than 21 cigarettes per day), alcohol addicts (more than 80g per day alcohol), subjects who are alcohol or drug dependence, subjects who are suspected of alcohol or drug dependence. 5. Subjects who are undergoing special facial care (e.g. facial appliances, aesthetic treatments, peels, laser treatments, etc.) which would affect this study. 6. Subjects who are pregnant or lactating, or subjects who expect to be pregnant during this study. 7. Subjects who have cognitive disorder or who have possibility of the disorder. 8. Subjects who participated and took the study drug in other clinical trials within twelve weeks prior to this study. 9. Subjects who are judges as unsuitable for this study by the principal investigator or subinvestigators.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between Stratum corneum water content and Advanced Glycation Endproducts.
- Secondary Outcome Measures
Name Time Method 1. Correlation between transepidermal water loss and AGEs. 2. Correlation between skin viscoelasticity and AGEs. 3. Adverse events.